Results 101 to 110 of about 15,930 (153)

Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary. [PDF]

Future Oncol
Rugo HS, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Brufsky A.   +7 more
europepmc   +1 more source

First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam. [PDF]

Front Oncol
Phan THD, Nguyen HQ.
europepmc   +1 more source

Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer. [PDF]

Transl Cancer Res
Chaki M, Morrow C, Ahlgren H.
europepmc   +1 more source

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. [PDF]

Breast Cancer
Yamanaka T, Sohn J, Sudo K, Mukai H, Yamamoto N, Chung CF, Lu YS, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Noguchi E, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K.   +30 more
europepmc   +1 more source

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer. [PDF]

Pharmaceutics
Wang J, Lamolinara A, Tomassoni D, Conti L, Cossu C, Di Lorenzo A, Giangrossi M, Lufrano D, Vaithianathan V, Orlando F, Olivieri F, Marcozzi S, Beghelli D, Belletti B, Amici A, Falconi M, Cavallo F, Iezzi M, Marchini C.   +18 more
europepmc   +1 more source

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance. [PDF]

Genome Med
Guarducci C, Abravanel D, Russo D, Prasad K, Fu J, Nagy Z, Rao V, Nardone A, Kuang Y, Feit A, Ma W, Feit GC, Hermida-Prado F, Heraud C, Munoz Gomez M, Garcia Cortes DE, Kurnia P, Gomez Tejeda Zanudo J, Li R, Qiu X, Cristea S, Feiglin A, Cheng YC, Lin NU, Tolaney SM, Malorni L, Sicinski P, Polyak K, Paweletz C, Long H, Stewart C, Michor F, Getz G, Brown M, Jeselsohn R.   +34 more
europepmc   +1 more source

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis. [PDF]

Front Med (Lausanne)
Lu M, Yuan L, Liu J, Dou Y, Cui J.
europepmc   +1 more source

A Pathway to Chordoma Treatment: A Review on CDKN2A and Therapeutic Targeting. [PDF]

Cancers (Basel)
Mohiuddin M, Vaca B, Haynal E, Bin-Alamer O, Zaki P, Abou-Al-Shaar H, Zenonos GA, Perez HA, Lopez-Gonzalez M, Gersey ZC.   +9 more
europepmc   +1 more source

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. [PDF]

Curr Oncol
Abdel-Razeq H, Sharaf B.
europepmc   +1 more source

Immune-Mediated Hepatotoxicity Associated With Ribociclib: A Multipatient Case Series and Management Strategy. [PDF]

Case Rep Oncol Med
Buchalter J, O Donovan H, Jordan E, Galvin Z, Walshe JM.   +4 more
europepmc   +1 more source